Sotera Health Company (SHC) Q2 2024 earnings summary

Executive summary

• Q2 2024 net revenues increased 8.3% year-over-year to $277 million, with Adjusted EBITDA up 7% to $137 million and Adjusted EBITDA margin at 49.7%.

• Net income for Q2 2024 was $8.8 million ($0.03/share), down from $24 million ($0.08/share) in Q2 2023, mainly due to higher interest expense and a $23.4 million loss on debt refinancing.

• All three business segments—Sterigenics, Nordion, and Nelson Labs—delivered volume growth, with Nordion leading at 29% revenue growth due to reactor harvest timing.

• The company completed a $2.3 billion debt refinancing, extending maturities to 2031 and reducing 2024 interest expense by $5 million.

• 2024 outlook reaffirmed, projecting 4–6% growth in net revenues and Adjusted EBITDA.

Financial highlights

• Q2 2024 revenue: $277 million, up 8.3% year-over-year (8.8% constant currency); Adjusted EBITDA: $137 million, up 7% year-over-year; margin at 49.7%.

• Q2 2024 Adjusted EPS: $0.19, down $0.01 year-over-year; net income: $8.8 million, down from $23.5 million, impacted by refinancing charges and higher interest expense.

• Q2 2024 service revenues grew 5.2% to $237.8 million; product revenues surged 32.9% to $38.8 million, mainly due to Nordion.

• Operating income rose 21.5% to $77 million; operating margin improved as operating expenses declined slightly.

• Cash and cash equivalents at June 30, 2024 were $246–248 million; liquidity at $646 million.

Outlook and guidance

• 2024 net revenues and Adjusted EBITDA expected to grow 4–6%; Adjusted EBITDA margin projected to approach 50%.

• Adjusted EPS guidance: $0.67–$0.75; interest expense expected at $165–$175 million; tax rate at 31.5–34.5%.

• Capital expenditures projected at $205–$225 million for 2024, with a step down in 2025 and 2026.

• Net leverage ratio expected to improve, with no M&A activity assumed in guidance.

• Management expects continued growth from capacity expansion projects in Sterigenics and Co-60 development in Nordion.